Product

Cell Line Generation and Process Development

May 13, 2009

For instance, we can apply a parallel strategy for cell line generation using multiple platforms. By using transient transfected cell pools, a small batch of a biopharmaceutical candidate can be produced at a very early stage. This enables you to reach milestones earlier and to check for critical aspects at an early stage (e.g. fate of compound in the body, proof of concept). At TNO, there is a close link between cell line generation and process development and safety and efficacy assessment. This raises the odds of having a process that can be transferred to a GMP facility in the shortest possible way, while managing CMC costs.